Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ahmad Awada

Showing results (101-110 of 311) with videos related to

Pageof 32
Sort By:
Critical Reviews in Oncology/Hematology|September 7, 2010
Prevention and management of major side effects of targeted agents in breast cancerOtto Metzger Filho, Kamal S Saini, Hatem A Azim, et al.
Investigational New Drugs|March 15, 2012
Clinical development of insulin-like growth factor receptor--1 (IGF-1R) inhibitors: at the crossroad?Andrea Gombos, Otto Metzger-Filho, Lissandra Dal Lago, et al.
Coronary Artery Disease|May 27, 2025
Recurrent coronary in-stent restenosis and rapidly progressive coronary artery disease as initial manifestation of immunoglobulin G4-related diseaseGeorgiana Pintea Bentea, Ahmad Awada, Vanessa Mary Crapanzano Minichello, et al.
Cancer Treatment Reviews|March 19, 2022
Molecular diagnosis and targeted treatment of advanced follicular cell-derived thyroid cancer in the precision medicine eraJaume Capdevila, Ahmad Awada, Dagmar Führer-Sakel, et al.
Ecancermedicalscience|January 26, 2019
Precision oncology: as much expectations as limitationsVitor Fiorin Vasconcellos, Leandro Machado Colli, Ahmad Awada, et al.
The Oncologist|January 1, 2008
Review: side effects of approved molecular targeted therapies in solid cancersChristian Widakowich, Gilberto de Castro, Evandro de Azambuja, et al.
ESMO Open|June 4, 2020
Metastatic breast cancer and pseudocirrhosis: an unknown clinical entityDan Engelman, Michel Moreau, Antonia Lepida, et al.
ESMO Open|December 5, 2019
CDK4/6 inhibition in low burden and extensive metastatic breast cancer: summary of an <i>ESMO Open-Cancer Horizons</i> pro and con discussionAhmad Awada, Joseph Gligorov, Guy Jerusalem, et al.
Head & Neck|October 22, 2014
Phase II trial evaluating the efficacy of sorafenib (BAY 43-9006) and correlating early fluorodeoxyglucose positron emission tomography-CT response to outcome in patients with recurrent and/or metastatic head and neck cancerYassine Lalami, Camillo Garcia, Patrick Flamen, et al.
Cancer Treatment Reviews|October 2, 2007
Novel cytotoxic drugs: old challenges, new solutionsGustavo F V Ismael, Daniela Dornelles Rosa, Max S Mano, et al.
Pageof 32

Showing results (101-110 of 311) with videos related to

Sort By:
Pageof 32
Critical Reviews in Oncology/Hematology|September 7, 2010
Prevention and management of major side effects of targeted agents in breast cancerOtto Metzger Filho, Kamal S Saini, Hatem A Azim, et al.
Investigational New Drugs|March 15, 2012
Clinical development of insulin-like growth factor receptor--1 (IGF-1R) inhibitors: at the crossroad?Andrea Gombos, Otto Metzger-Filho, Lissandra Dal Lago, et al.
Coronary Artery Disease|May 27, 2025
Recurrent coronary in-stent restenosis and rapidly progressive coronary artery disease as initial manifestation of immunoglobulin G4-related diseaseGeorgiana Pintea Bentea, Ahmad Awada, Vanessa Mary Crapanzano Minichello, et al.
Cancer Treatment Reviews|March 19, 2022
Molecular diagnosis and targeted treatment of advanced follicular cell-derived thyroid cancer in the precision medicine eraJaume Capdevila, Ahmad Awada, Dagmar Führer-Sakel, et al.
Ecancermedicalscience|January 26, 2019
Precision oncology: as much expectations as limitationsVitor Fiorin Vasconcellos, Leandro Machado Colli, Ahmad Awada, et al.
The Oncologist|January 1, 2008
Review: side effects of approved molecular targeted therapies in solid cancersChristian Widakowich, Gilberto de Castro, Evandro de Azambuja, et al.
ESMO Open|June 4, 2020
Metastatic breast cancer and pseudocirrhosis: an unknown clinical entityDan Engelman, Michel Moreau, Antonia Lepida, et al.
ESMO Open|December 5, 2019
CDK4/6 inhibition in low burden and extensive metastatic breast cancer: summary of an <i>ESMO Open-Cancer Horizons</i> pro and con discussionAhmad Awada, Joseph Gligorov, Guy Jerusalem, et al.
Head & Neck|October 22, 2014
Phase II trial evaluating the efficacy of sorafenib (BAY 43-9006) and correlating early fluorodeoxyglucose positron emission tomography-CT response to outcome in patients with recurrent and/or metastatic head and neck cancerYassine Lalami, Camillo Garcia, Patrick Flamen, et al.
Cancer Treatment Reviews|October 2, 2007
Novel cytotoxic drugs: old challenges, new solutionsGustavo F V Ismael, Daniela Dornelles Rosa, Max S Mano, et al.
Pageof 32